Terbinafine Management for Tinea Capitis

Dosing Recommendations

Organism‑Specific Treatment Strategies

Pre‑Treatment Evaluation

Treatment Duration and Management of Failure

Formulations and Administration

Safety Monitoring

Clinical Pitfalls to Avoid

Adjunctive Measures

Terbinafine Use in Tinea Capitis: Evidence‑Based Recommendations

Comparative Efficacy by Fungal Species

• Griseofulvin is more effective than standard‑dose terbinafine for Microsporum canis infections; clinical cure rates are higher with griseofulvin administered for 8 weeks. 4
• Standard‑dose terbinafine achieves insufficient drug concentrations in the hair shaft of pre‑pubertal children, limiting its ability to eradicate Microsporum arthroconidia because the drug is not excreted in sweat or sebum in this population. 4

Dosing Adjustments for Microsporum Infections

• When terbinafine is chosen for M. canis, the dose should be doubled (e.g., 125 mg/day for children 10–25 kg and 250 mg/day for those >25 kg) to improve efficacy, although cure rates remain only about 65–67 %. 4

Available Formulations

• A granule formulation (125 mg or 187.5 mg) is marketed in some regions for children older than 4 years and can be mixed with food to facilitate administration. 4
• This granule formulation is licensed in the United States but not approved in the United Kingdom. 4

Adjunctive Measures

• Antifungal shampoos (e.g., ketoconazole 2 %, selenium sulfide 1 %, povidone‑iodine) reduce environmental spore load and transmission risk, but they do not replace systemic therapy for achieving cure. 4

Clinical Pitfalls to Avoid

• Do not rely on standard terbinafine dosing for M. canis; consider griseofulvin as the preferred first‑line agent because of its superior efficacy. 4

Oral Terbinafine Dosing Guidelines for Tinea Capitis

Standard Weight‑Based Dosing for Trichophyton Species

• For patients with Trichophyton‑caused tinea capitis, the recommended oral terbinafine dose is weight‑adjusted:
  
  • ≤ 20 kg → 62.5 mg once daily
  • 20–40 kg → 125 mg once daily
  • > 40 kg (including adults) → 250 mg once daily
  • Treatment duration: 2–4 weeks 4

Adjusted Dosing for Microsporum Species

• The standard terbinafine regimen is ineffective against Microsporum canis because drug concentrations in the pre‑pubertal scalp are insufficient; the dose must be doubled.
• Revised weight‑based regimen for Microsporum infections:
  
  • 10–25 kg → 125 mg once daily (double dose)
  • > 25 kg → 250 mg once daily (double dose)
  • Treatment duration: 8–12 weeks 4
• For Microsporum infections, oral griseofulvin at 20–25 mg/kg/day for 8 weeks is preferred over terbinafine, showing superior cure rates 4

Treatment Duration and Management of Therapeutic Failure

• If clinical cure is not achieved, extend the oral antifungal course to 12–18 weeks or switch to an alternative systemic agent 4
• In resistant cases, higher terbinafine doses up to 25 mg/kg/day may be required 4

Formulations and Availability

• Granular formulations (125 mg or 187.5 mg) are available in some regions for children older than 4 years and can be mixed with food to aid administration; these granules are licensed in the United States but not in the United Kingdom 4

Adjunctive Topical Measures

• Antifungal shampoos (e.g., ketoconazole 2 %, selenium sulfide 1 %, povidone‑iodine) can lower environmental spore burden and reduce transmission risk, but they do not replace systemic therapy; their efficacy in decreasing spore spread has been demonstrated 4

Management of Bacterial Superinfection (Impetiginization) During Oral Antifungal Therapy for Tinea Capitis

Recognition of Bacterial Superinfection

• Clear serous discharge from a tinea capitis lesion in a child receiving oral terbinafine or griseofulvin signals secondary bacterial superinfection and warrants the addition of antibiotics while the antifungal regimen is maintained. 5
• Serous or honey‑colored crusting suggests infection with Staphylococcus aureus or Streptococcus pyogenes. 5
• New or increased erythema, warmth, or tenderness beyond the baseline inflammatory changes indicates bacterial colonization or infection. 5
• Thick, opaque (purulent) discharge denotes a more advanced bacterial infection. 5
• Systemic manifestations such as fever, malaise, or worsening regional lymphadenopathy may require oral rather than topical antibiotic therapy. 5

Continuation of Antifungal Therapy

• The oral antifungal (terbinafine for Trichophyton or griseofulvin for Microsporum) should be continued without interruption to avoid treatment failure and relapse. 5
• Terbinafine dosing is weight‑based (≤20 kg → 62.5 mg daily; 20–40 kg → 125 mg daily; >40 kg → 250 mg daily) for a full 2–4‑week course. 5
• Griseofulvin is given at 15–20 mg/kg/day with a high‑fat meal for a full 6–8‑week course. 5

Antibacterial Therapy

Topical agents (localized, mild impetiginization)

• Mupirocin 2 % ointment applied three times daily for 5–7 days is the first‑line topical antibiotic. 5
• Fusidic acid 2 % cream three times daily is an alternative where available. 5

Oral agents (extensive or severe bacterial superinfection)

• Cephalexin 25–50 mg/kg/day divided into 3–4 doses (maximum 4 g/day) for 7–10 days is the first‑line oral antibiotic. 5
• Azithromycin 10 mg/kg once daily (maximum 500 mg) for 5 days is an alternative for patients with penicillin allergy. 5
• Trimethoprim‑sulfamethoxazole 8–12 mg/kg/day (based on the trimethoprim component) divided twice daily for 7–10 days provides MRSA coverage when suspected or confirmed. 5

Adjunctive Scalp Hygiene

• Antifungal shampoo (selenium sulfide 1 % or ketoconazole 2 %) used 2–3 times weekly throughout systemic therapy reduces spore burden and helps prevent secondary bacterial colonization. 5

Monitoring, Reassessment, and Referral

• Reassess at 7–10 days: if serous discharge resolves, continue the oral antifungal to completion and monitor for mycological cure. 5
• If discharge persists or worsens despite antibiotics, obtain bacterial culture and sensitivity and adjust therapy accordingly. 5
• Persistent serous discharge beyond 10 days of appropriate antibiotic treatment warrants referral to dermatology or infectious‑disease specialists. 5
• Extensive kerion with risk of permanent scarring alopecia, suspected MRSA or other resistant organisms, and systemic signs of sepsis (fever > 38.5 °C, lethargy, refusal to feed) all indicate the need for specialist referral. 5

Evidence Strength and Guideline Source

• The recommendations are derived from the British Association of Dermatologists 2014 guideline and are based on expert opinion and general dermatology principles for impetiginization of inflammatory scalp conditions; no formal grading of evidence is provided. 5